Wells Fargo has recently downgraded its investment rating for cell therapy company ARCELLX, INC. from "Overweight" to "Equal Weight".
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
However, the institution has simultaneously raised the target stock price from $100 to $115, demonstrating recognition of the company's long-term value. This rating adjustment reflects the analysts' balanced consideration between short-term risks and long-term potential. The upward revision of the target price may be based on ARCELLX's technological advancements in the CAR-T cell therapy field or positive signals from clinical trial data.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
HPE CFO Sees No Changes in Memory Supply Until Fiscal 2028 -- Market Talk
Dow Jones•2026/09/03 15:23
Assaí denies improper payments in ICMS-ST tax reimbursement services case
Reuters•2026/09/03 15:22
Blue Moon Metals Acquiring Land And Water Rights Package in Nevada For $8 Million in Cash and Shares
MT newswire•2026/09/03 15:21
Crypto prices
MoreBitcoin
BTC
$80,750.59
+4.94%
Ethereum
ETH
$2,485.48
+4.10%
Tether USDt
USDT
$0.9998
+0.04%
BNB
BNB
$720
+5.21%
XRP
XRP
$1.44
+8.40%
USDC
USDC
$0.9999
+0.01%
Solana
SOL
$104.35
+5.52%
TRON
TRX
$0.3299
+1.79%
Hyperliquid
HYPE
$83.71
+3.32%
Zcash
ZEC
$891.1
+9.96%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now